*ST天山：2025年前三季度净利润约-1170万元

Group 1 - *ST Tianshan reported a revenue of approximately 58.48 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 44.98% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 11.7 million yuan [1] - The basic earnings per share showed a loss of 0.0374 yuan [1] Group 2 - As of the report, the market capitalization of *ST Tianshan is 2.6 billion yuan [2] - The Chinese innovative drug sector has generated 80 billion US dollars in overseas licensing this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is facing challenges in fundraising [2]